Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable Gastroesophageal Junction Adenocarcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07609667
What this trial is testing

SKB315 in Combination Therapy in Patients With Advanced or Metastatic GC/ GEJ Adenocarcinoma

Who this might be right for
Gastroesophageal Junction Adenocarcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 80
Early research (Phase 1)Study completedNCT02572687
What this trial is testing

Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaNon-Small Cell Lung Cancer+1 more
Eli Lilly and Company 85
Large-scale testing (Phase 3)Not Yet RecruitingNCT07700979
What this trial is testing

Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

Who this might be right for
Gastric / Gastroesophageal Junction Adenocarcinoma
Akeso 900
Large-scale testing (Phase 3)WithdrawnNCT04859582
What this trial is testing

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension

Who this might be right for
Stomach Neoplasms
Merck Sharp & Dohme LLC
Testing effectiveness (Phase 2)Looking for participantsNCT06932068
What this trial is testing

Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma

Who this might be right for
HER2 NegativeLow PD-L1 ExpressingUnresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Qilu Hospital of Shandong University 77
Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine 156
Testing effectiveness (Phase 2)UnknownNCT05608785
What this trial is testing

Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes

Who this might be right for
Gastric CancerGastroesophageal-junction Cancer
Henan Cancer Hospital 45
Testing effectiveness (Phase 2)Study completedNCT04984733
What this trial is testing

Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer

Who this might be right for
Adenocarcinoma - GEJCancer of Esophagus
University of Southampton 13
Testing effectiveness (Phase 2)Study completedNCT00711243
What this trial is testing

Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor

Who this might be right for
Gastric CancerUnspecified Adult Solid Tumor, Protocol Specific
Northwestern University 59
Testing effectiveness (Phase 2)Active Not RecruitingNCT03641313
What this trial is testing

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+5 more
National Cancer Institute (NCI) 17
Testing effectiveness (Phase 2)Study completedNCT04014075
What this trial is testing

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Who this might be right for
Adenocarcinoma Gastric Stage IV With MetastasesAdenocarcinoma - GEJ
Daiichi Sankyo 79
Large-scale testing (Phase 3)Study completedNCT03777657
What this trial is testing

Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

Who this might be right for
Gastric, or Gastroesophageal Junction Adenocarcinoma
BeiGene 997
Testing effectiveness (Phase 2)Study completedNCT00074009
What this trial is testing

Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Cancer
Memorial Sloan Kettering Cancer Center
Large-scale testing (Phase 3)Study completedNCT05008783
What this trial is testing

AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Akeso 610
Testing effectiveness (Phase 2)Study completedNCT00253370
What this trial is testing

Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionMetastatic Gastric CancerAdvanced Unresectable Gastric Cancer
National Cancer Institute (NCI) 44
Testing effectiveness (Phase 2)UnknownNCT04263870
What this trial is testing

Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

Who this might be right for
Gastroesophageal Junction AdenocarcinomaStomach AdenocarcinomaLocally Advanced Unresectable Gastric Adenocarcinoma+1 more
Sichuan University 36
Testing effectiveness (Phase 2)Study completedNCT00032123
What this trial is testing

Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

Who this might be right for
Esophageal CancerGastric Cancer
SWOG Cancer Research Network
Large-scale testing (Phase 3)Looking for participantsNCT05427383
What this trial is testing

KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

Who this might be right for
Stomach Cancer
Shanghai JMT-Bio Inc. 286
Testing effectiveness (Phase 2)Study completedNCT01585987
What this trial is testing

An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy

Who this might be right for
Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction
Bristol-Myers Squibb 143
Early research (Phase 1)Looking for participantsNCT05365581
What this trial is testing

ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction (GEJ) AdenocarcinomaPancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc. 398
Next Page